Is ALRN or NOBL a better dividend investment in 2026?

ALRN currently yields 94.79% with a 5% 5-year dividend growth rate. NOBL yields 2.17% with 5% growth. The better choice depends on your goal: ALRN offers higher current income.

What is the dividend yield difference between ALRN and NOBL?

ALRN has a forward dividend yield of 94.79% ($2.00/share annually). NOBL yields 2.17% ($2.27/share annually). The yield gap is 92.62 percentage points.

Home › Compare › ALRN vs NOBL

ALRN vs NOBL: Dividend Comparison 2026

ALRN yields 94.79% · NOBL yields 2.17%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ALRN wins by $3.12M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ALRN

● Live price

94.79%

Share price

$2.11

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$3.14M

Annual income

$1,021,196.07

Full ALRN calculator →

NOBL

● Live price

2.17%

Share price

$104.67

Annual div

$2.27

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$22.9K

Annual income

$249.78

Full NOBL calculator →

Portfolio growth — ALRN vs NOBL

📍 ALRN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ALRN	NOBL
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ALRN + NOBL cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ALRN pays

NOBL pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALRN

Annual income on $10K today (after 15% tax)

$8,056.87/yr

After 10yr DRIP, annual income (after tax)

$868,016.66/yr

NOBL

Annual income on $10K today (after 15% tax)

$184.52/yr

After 10yr DRIP, annual income (after tax)

$212.31/yr

At 15% tax rate, ALRN beats the other by $867,804.35/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALRN + NOBL for your $10,000?

ALRN: 50%NOBL: 50%

100% NOBL50/50100% ALRN

Portfolio after 10yr

$1.58M

Annual income

$510,722.92/yr

Blended yield

32.29%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on ALRN right now

ALRN

Analyst Ratings

Buy

Hold

Consensus: Buy

Altman Z

-26.5

Piotroski

1/9

NOBL

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALRN buys

NOBL buys

No recent congressional trades found for ALRN or NOBL in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricALRNNOBL

Forward yield	94.79% ✓	2.17%
Annual dividend / share	$2.00	$2.27 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$3.14M	$22.9K ✓
Annual income after 10y	$1,021,196.07 ✓	$249.78
Total dividends collected	$2.79M ✓	$2.3K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: ALRN vs NOBL ($10,000, DRIP)

Year	ALRN Portfolio	ALRN Income/yr	NOBL Portfolio	NOBL Income/yr	Gap
1← crossover	$20,179	$9,478.67	$10,917	$217.08	+$9.3K → ALRN
2	$39,467	$17,875.42	$11,903	$221.48	+$27.6K → ALRN
3	$74,904	$32,674.56	$12,962	$225.68	+$61.9K → ALRN
4	$138,103	$57,956.24	$14,099	$229.68	+$124.0K → ALRN
5	$247,636	$99,865.76	$15,319	$233.49	+$232.3K → ALRN
6	$432,328	$167,356.66	$16,628	$237.10	+$415.7K → ALRN
7	$735,650	$273,059.80	$18,033	$240.53	+$717.6K → ALRN
8	$1,221,388	$434,242.66	$19,539	$243.78	+$1.20M → ALRN
9	$1,980,686	$673,800.19	$21,154	$246.86	+$1.96M → ALRN
10	$3,140,530	$1,021,196.07	$22,884	$249.78	+$3.12M → ALRN

ALRN vs NOBL: Complete Analysis 2026

ALRN — Stock

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

Full ALRN Calculator →

NOBL — ETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →

📬

Get this ALRN vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALRN vs SCHD ALRN vs JEPI ALRN vs O ALRN vs KO ALRN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.